Kanghong Pharmaceutical's daily limit!Pharmaceutical ETF Fund (159838) continues to get capital inflows, and the trend is popular

Today, the three major indexes of A shares fell collectively. The Medicine 50 Index flushed against the trend, rising 0.2%, and the premium at the Pharmaceutical ETF Fund (159838) was slightly rose by 0.4%.The fund has continuously received net inflow of funds in the past week, the fund share continues to grow, and it is favored by investors!Among individual stocks, due to the rapid growth of net profit in the semi -annual report of 2022, Kanghong Pharmaceutical's daily limit, China Resources Sanjiu, Aimei, Aier Eye, Wantai Bio and other stocks have risen.

Guojin Securities stated that the pharmaceutical sector focuses on the opportunities for dual repair and valuation of performance and valuation, and pays attention to the progress of innovative drug research and development.The industry is highly prosperous, orders and performance continue to improve, and the market emotions fluctuate and recover. Continue to be optimistic about the semi -annual report of the CXO sector.At the same time, continue to be optimistic about the upstream and pharmaceutical supply chain of the upstream of the industrial chain and the pharmaceutical upstream and midstream manufacturing with export advantages.The raw material pharmaceutical sector 21H2 is affected by factors such as exchange rates, raw materials price increases and freight, and the profitability has declined. It is optimistic about the investment opportunities brought about by the improvement of profitability of the raw material pharmaceutical sector in the second half of the 22nd years.

- END -